thyroid cancer
Eli Lilly shares topline results from LIBRETTO-531 trial for Retevmo
August 23, 2023Research and Development Eli Lilly, Oncology, Retevmo, clinical trial, slpercatinib, thyroid cancer
Eli Lilly has announced topline results from the LIBRETTO-531 study assessing Retevmo (selpercatinib) as an initial treatment for patients with …
FDA approves Novartis combo in rare thyroid cancer subtype
May 8, 2018Manufacturing and Production, Sales and Marketing Cancer, FDA, Tafinlar, mekinist, thyroid cancer
The FDA has announced its decision to approve the use of Novartis’ combination of Tafinlar (dabrafenib) and Mekinist (trametinib) in …
NICE recommends thyroid cancer drug trio for NHS use
February 20, 2018Manufacturing and Production, Sales and Marketing Bayer, Cancer, Cometriq, Eisai, Lenvima, NICE, Nexavar, ipsen, pharma, thyroid cancer
NICE has announced its decision to recommend that three separate treatments for thyroid cancer should be made available for use …
Evaluation of Eisai’s advanced thyroid cancer treatment blocked until 2018 in England
August 2, 2016Manufacturing and Production, Sales and Marketing CDF, Eisai, Lenvima, NHS, NICE, lenvatinib, thyroid cancer
Following negotiations between the NHS, NICE and Japanese pharmaceutical company Eisai, differentiated thyroid cancer (RAI-R DTC) drug lenvima (levatinib) has …
Caprelsa approved in Europe for thyroid cancer
February 21, 2012Sales and Marketing AstraZeneca, Caprelsa, FDA, RET, thyroid cancer
The European Commission has approved AstraZeneca’s thyroid cancer pill Caprelsa. Caprelsa (vandetanib) is now available in Europe for the treatment …
Zactima extends progression free survival in other thyroid cancers
September 13, 2010Research and Development thyroid cancer, zactima
New data suggests patients with the more common forms of thyroid cancer respond to AstraZeneca’s Zactima. The drug has already …
ASCO 2010: The Hedgehog Pathway and other ways to target cancer
August 19, 2010Research and Development ASCO, Cancer, thyroid cancer
The American Society of Clinical Oncology conference, one of the most important dates in the pharmaceutical industry’s calendar, took place …
Zactima promising in rare thyroid cancer
June 11, 2010Research and Development, Sales and Marketing AstraZeneca, thyroid cancer, zactima
AstraZeneca’s Zactima (vandetanib) will be filed with regulators later this year as a treatment for thyroid cancer after promising results. …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
